SCHEMBL2374649

SCHEMBL2374649

CN(C)C1CCN(C(=O)[C@H](Cc2ccccc2)N(Cc2ccc(-c3ccccn3)cc2)C(=O)/C=C/c2ccc(C(F)(F)F)cc2)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 2/20 0.39
DPP7 Q9UHL4 1/20 0.39
NPY2R P49146 1/20 0.38
MTTP P55157 1/20 0.37
DRD2 P14416 3/20 0.37
HTR2A P28223 3/20 0.37
HTR2C P28335 3/20 0.37
HTR2B P41595 3/20 0.37
SIGMAR1 Q99720 2/20 0.37
NOS3 P29474 1/20 0.37
NOS1 P29475 1/20 0.37
NOS2 P35228 1/20 0.37
CYP3A4 P08684 1/20 0.36
UGCG Q16739 1/20 0.36
HTR5A P47898 3/20 0.36
MCHR1 Q99705 2/20 0.36
KCNH2 Q12809 2/20 0.36
HTR1A P08908 1/20 0.35
DRD4 P21917 1/20 0.35
HTR1D P28221 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2374659 1.00 DPP4 (0.39) DPP4DPP7NPY2RMTTPDRD2
SCHEMBL2374654 1.00 DPP4 (0.39) DPP4DPP7NPY2RMTTPDRD2
SCHEMBL2331211 0.96 DPP4 (0.41) DPP4DPP7NPY2RMTTPDRD2
SCHEMBL2339451 0.96 DPP4 (0.41) DPP4DPP7NPY2RMTTPDRD2
SCHEMBL2331207 0.96 DPP4 (0.41) DPP4DPP7NPY2RMTTPDRD2
SCHEMBL2339456 0.96 DPP4 (0.41) DPP4DPP7NPY2RMTTPDRD2
SCHEMBL2331213 0.96 DPP4 (0.41) DPP4DPP7NPY2RMTTPDRD2
SCHEMBL2375937 0.92 DPP4 (0.38) DPP4DPP7DRD2HTR2AHTR2C
SCHEMBL2375942 0.92 DPP4 (0.38) DPP4DPP7DRD2HTR2AHTR2C
SCHEMBL2375940 0.92 DPP4 (0.38) DPP4DPP7DRD2HTR2AHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110224210-A1 NOVEL BIS-AMIDES AS ANTI-MALARIAL AGENTS ACTELION PHARMACEUTICALS LTD. (CH) 2011-09-15 US claimed
US-20110224210-A1 NOVEL BIS-AMIDES AS ANTI-MALARIAL AGENTS ACTELION PHARMACEUTICALS LTD. (CH) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224210-A1 NOVEL BIS-AMIDES AS ANTI-MALARIAL AGENTS CTSA, BECN1, HDAC6 DPP4 754/4885DPP7 678/4885NPY2R 4667/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.